featured-image

( MENAFN - GlobeNewsWire - Nasdaq) DURHAM, N.C., May 20, 2024 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”) , a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare cardiopulmonary diseases, today announced the presentation of new lung deposition modeling data for AER-901 at the American Thoracic Society (ATS) 2024 International Conference being held May 17-22, 2024, in San Diego, California.

These new data generated by FLUIDDA, Inc., using their proprietary Functional Respiratory Imaging (FRI) and Rapid Deposition Analysis (RDA) platforms, predicted efficient deposition of AER-901 throughout the lung in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) or pulmonary arterial hypertension (PAH), as well as healthy volunteers. When compared with a hypothetical dry-powder-inhaled imatinib (DPI-Imatinib) at equivalent nominal doses, total imatinib lung deposition with AER-901 was predicted to be more than 2 times greater across all three populations, and deposition in the deep lung was predicted to be more than 3 times greater.



“We believe that these new modeling data, generated in collaboration with FLUIDDA, strongly highlight the differentiated AER-901 profile across multiple forms of pulmonary hypertension,” said Anne Whitaker, Chairwoman and Chief Executive Officer of Aerami.“By optimizing delivery of imatinib to the lungs with AER-901, we believe that we can better tar.

Back to Health Page